T1	HMM 1017 1033	epigastric pain)
T2	HMM 1139 1163	total number of PVC/hour
T3	HMM 1219 1323	A reduction in PVC/hour of more than 70 per cent was seen in 7 patients with C and in 9 patients with P.
T4	HMM 1324 1420	C was better tolerated than P on the basis of both clinical and electrocardiographic parameters.
T5	HMM 1455 1472	adverse reactions
T6	HMM 1526 1678	A more than 20 per cent increase in QRS was seen in 7 patients with C and in 10 patients with P, the figures for PR being 2 and 6 patients respectively.
T7	HMM 1700 1728	proarrhythmic effect with P.
T8	HMM 1729 1868	Plasma levels of C were significantly higher in responders (328 +/- 149 ng/ml) than in non-responders (137 +/- 41 ng/ml, p less than 0.05).
T9	HMM 1869 2008	No significant difference was found concerning plasma levels of P (578 +/- 477 ng/ml compared with 646 +/- 457 ng/ml, p greater than 0.05).
T10	HMM 2028 2055	efficacy/tolerability ratio
